MX2020012297A - Biomarcadores sanguíneos de accidente cerebrovascular. - Google Patents
Biomarcadores sanguíneos de accidente cerebrovascular.Info
- Publication number
- MX2020012297A MX2020012297A MX2020012297A MX2020012297A MX2020012297A MX 2020012297 A MX2020012297 A MX 2020012297A MX 2020012297 A MX2020012297 A MX 2020012297A MX 2020012297 A MX2020012297 A MX 2020012297A MX 2020012297 A MX2020012297 A MX 2020012297A
- Authority
- MX
- Mexico
- Prior art keywords
- blood
- ischemic
- brain
- stroke
- expression
- Prior art date
Links
- 239000008280 blood Substances 0.000 title abstract 7
- 210000004369 blood Anatomy 0.000 title abstract 7
- 208000006011 Stroke Diseases 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 title abstract 3
- 206010008190 Cerebrovascular accident Diseases 0.000 title 1
- 208000026106 cerebrovascular disease Diseases 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 4
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 241000282553 Macaca Species 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000011970 concomitant therapy Methods 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000010195 expression analysis Methods 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000002493 microarray Methods 0.000 abstract 1
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305600 | 2018-05-16 | ||
| PCT/EP2019/062653 WO2019219831A1 (en) | 2018-05-16 | 2019-05-16 | Blood biomarkers of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012297A true MX2020012297A (es) | 2021-03-25 |
Family
ID=62386311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012297A MX2020012297A (es) | 2018-05-16 | 2019-05-16 | Biomarcadores sanguíneos de accidente cerebrovascular. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12247257B2 (https=) |
| EP (1) | EP3794355A1 (https=) |
| JP (2) | JP7463351B2 (https=) |
| KR (1) | KR20210049026A (https=) |
| CN (1) | CN112424609A (https=) |
| AU (1) | AU2019270404B2 (https=) |
| BR (1) | BR112020023259A2 (https=) |
| CA (1) | CA3100171A1 (https=) |
| IL (1) | IL278666B2 (https=) |
| MA (1) | MA52617A (https=) |
| MX (1) | MX2020012297A (https=) |
| SG (1) | SG11202011369VA (https=) |
| WO (1) | WO2019219831A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220093267A1 (en) * | 2019-01-22 | 2022-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Noninvasive real-time patient-specific assessment of stroke severity |
| CN114107487B (zh) * | 2021-12-23 | 2024-01-09 | 太原市精神病医院 | 一种可用于诊断脑卒中的产品 |
| JP2023111774A (ja) * | 2022-01-31 | 2023-08-10 | 国立研究開発法人国立循環器病研究センター | 再灌流療法の適用を決定するバイオマーカー |
| CN116705296B (zh) * | 2023-06-06 | 2024-09-13 | 中国科学院深圳先进技术研究院 | 一种基于常规mri序列对gbm患者进行风险分层的方法及系统 |
| WO2025151599A1 (en) * | 2024-01-09 | 2025-07-17 | Morehouse School Of Medicine | Rna-based method for stroke assessment and treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU2002241520A1 (en) * | 2000-11-28 | 2003-03-03 | University Of Cincinnati | Blood assessment of injury |
| US9005891B2 (en) | 2009-11-10 | 2015-04-14 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
| US9410204B2 (en) | 2012-01-07 | 2016-08-09 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| US20150274815A1 (en) * | 2012-09-25 | 2015-10-01 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Treatment of central nervous system (cns) injury |
| JP2016507235A (ja) * | 2013-02-01 | 2016-03-10 | ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ | 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法 |
| US11021750B2 (en) * | 2013-10-13 | 2021-06-01 | The Research Foundation For State University Of Newyork | Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof |
| CN108291330A (zh) * | 2015-07-10 | 2018-07-17 | 西弗吉尼亚大学 | 卒中和卒中严重性的标志物 |
| US20190311789A1 (en) * | 2016-10-03 | 2019-10-10 | West Virginia University | Computer implemented discovery of biomarkers for blood brain barrier disruption |
-
2019
- 2019-05-16 SG SG11202011369VA patent/SG11202011369VA/en unknown
- 2019-05-16 EP EP19723441.2A patent/EP3794355A1/en active Pending
- 2019-05-16 CN CN201980047566.0A patent/CN112424609A/zh active Pending
- 2019-05-16 WO PCT/EP2019/062653 patent/WO2019219831A1/en not_active Ceased
- 2019-05-16 MX MX2020012297A patent/MX2020012297A/es unknown
- 2019-05-16 JP JP2021514483A patent/JP7463351B2/ja active Active
- 2019-05-16 KR KR1020207035973A patent/KR20210049026A/ko not_active Ceased
- 2019-05-16 BR BR112020023259-9A patent/BR112020023259A2/pt unknown
- 2019-05-16 MA MA052617A patent/MA52617A/fr unknown
- 2019-05-16 US US17/054,820 patent/US12247257B2/en active Active
- 2019-05-16 IL IL278666A patent/IL278666B2/en unknown
- 2019-05-16 CA CA3100171A patent/CA3100171A1/en active Pending
- 2019-05-16 AU AU2019270404A patent/AU2019270404B2/en active Active
-
2024
- 2024-03-27 JP JP2024051056A patent/JP2024075761A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA52617A (fr) | 2021-03-24 |
| KR20210049026A (ko) | 2021-05-04 |
| EP3794355A1 (en) | 2021-03-24 |
| AU2019270404B2 (en) | 2025-04-17 |
| SG11202011369VA (en) | 2020-12-30 |
| AU2019270404A2 (en) | 2020-12-17 |
| IL278666B1 (en) | 2025-02-01 |
| US20210214793A1 (en) | 2021-07-15 |
| JP2021523744A (ja) | 2021-09-09 |
| AU2019270404A1 (en) | 2020-12-10 |
| JP2024075761A (ja) | 2024-06-04 |
| IL278666A (en) | 2020-12-31 |
| BR112020023259A2 (pt) | 2021-02-23 |
| US12247257B2 (en) | 2025-03-11 |
| JP7463351B2 (ja) | 2024-04-08 |
| CA3100171A1 (en) | 2019-11-21 |
| WO2019219831A1 (en) | 2019-11-21 |
| IL278666B2 (en) | 2025-06-01 |
| CN112424609A (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012297A (es) | Biomarcadores sanguíneos de accidente cerebrovascular. | |
| CO2018007417A2 (es) | Identificación, fabricación y uso de neoantígeno | |
| Zhu et al. | Application of nanomaterials in the bioanalytical detection of disease-related genes | |
| CY1121741T1 (el) | Χρηση του μεγεθους θραυσματων εξωκυτταριου dna για τον προσδιορισμο παραλλαγης αριθμου αντιγραφων | |
| CO2018012911A2 (es) | Análisis de datos telemáticos dentro de poblaciones heterogéneas de vehículos | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| CY1118376T1 (el) | Υδροχλωριδιο παραγωγου πουρινονης | |
| MX2020004949A (es) | Arn no codificante para la deteccion de cancer. | |
| EP4414991A3 (en) | Using size and number aberrations in plasma dna for detecting cancer | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| EP2663656A1 (en) | Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| EP4484572A3 (en) | Identification and use of circulating nucleic acid tumor markers | |
| MX2015008177A (es) | Evaluacion de la actividad de la via de señalizacion celular utilizando combinacion(es) lineal(es) de expresiones de genes objetivo. | |
| MX2017010836A (es) | Panel biomarcador para la deteccion de cancer. | |
| MX2024004195A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
| MX2018013621A (es) | Metodo, matriz y uso de estos. | |
| MX2020007852A (es) | Metodos para el tratamiento de la atrofia muscular espinal. | |
| BR112015019567A8 (pt) | inibidor de wnt, seu uso e métodos para prognosticar sensibilidade ao mesmo, e composição farmacêutica | |
| PE20180930A1 (es) | Composiciones y metodos para la vigilancia activa del cancer de prostata | |
| CY1120139T1 (el) | Χρηση κλαδριβινης για αντιμετωπιση οπτικης νευρομυελιτιδας | |
| Martinez-Martin et al. | Measurement of nonmotor symptoms in clinical practice | |
| AR097489A1 (es) | Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica | |
| CO2018011808A1 (es) | Método in vitro para identificar genotípicamente ambos alelos de al menos un locus de un gen hla en muestras de adn genómico de un sujeto | |
| AR099950A1 (es) | Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina |